If retatrutide follows the same pattern, we would expect an Eli Lilly regulatory filing in late 2026, MHRA approval in late 2027 to mid-2028, and NHS access through NICE from 2029 at the earliest
The 2 mg dose is primarily designed as a well-tolerated introductory step before escalating to more effective maintenance doses like 8 mg or 12 mg
This response is entirely normal and shared by the majority of new injectable medication users
Pratley RE, Aroda VR, Lingvay I, Ldemann J, Andreassen C, Navarria A et al (2018) Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial
Tips & Challenges Read Labels Carefully Not all "GLP-1 boosting" foods are created equal